The American Society of Clinical Oncology recommends a stepped-care model for the management of anxiety and depression in adult cancer survivors in its updated guideline
Vaccine: Aiming Too High: Shoulder Injury Related to Vaccine Administration (SIRVA): A Case Series Vaccine: Prevalence of Pain and Fear as Barriers to Vaccination in
Progression-free survival was increased in patients with primary advanced or recurrent endometrial cancer — particularly those with mismatch repair–deficient (dMMR), microsatellite instability–high (MSI-H) tumors —
Adding pembrolizumab to standard chemotherapy increased progression-free survival In patients with advanced or recurrent endometrial cancer, compared with chemotherapy alone, researchers report. “The efficacy curves
In patients with cancer and venous thromboembolism (VTE) events, prophylaxis of recurrence with direct oral anticoagulants (DOACs) was noninferior to low-molecular-weight heparins (LMWHs), a study shows.
A dual inhibitor of the mutant IDH1 and IDH2 enzymes, vorasidenib significantly improved progression-free survival and delayed the time to the next intervention In patients with
In a phase 3, randomized, double-blind trial of patients with hormone receptor–positive advanced breast cancer, progression-free survival was significantly longer with the AKT inhibitor capivasertib
In a real-world study, the safety and efficacy of immune checkpoint inhibitors (ICIs) were similar when used for a variety of cancer types in people living
In patients with acute myeloid leukemia (AML) positive for internal tandem duplication (ITD) mutations of FLT3, the selective type 2 FLT3 inhibitor quizartinib plus chemotherapy improved overall
Based on an analysis of 170 FDA-approved drugs across 455 cancer indications from 2000 to 2022, researchers conclude that a “distinct ultra-orphan designation with greater